Rahnavardi Mohammad, Yan Tristan D, Cao Christopher, Vallely Michael P, Bannon Paul G, Wilson Michael K
Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital, The University of Sydney, Missenden Road, Camperdown, Sydney, Australia.
Ann Thorac Cardiovasc Surg. 2011;17(5):435-45. doi: 10.5761/atcs.oa.10.01653. Epub 2011 Jul 13.
Pulmonary thromboendarterectomy (PTE) is a treatment option for patients with chronic thromboembolic pulmonary hypertension (CTEPH). The present systematic review was performed to assess the safety and efficacy of PTE for CTEPH.
A systematic review was performed, and six electronic databases were searched for published studies from January 1999 to February 2010. All articles that presented morbidity and mortality data, survival data or preoperative and postoperative pulmonary hemodynamic indices were included. The primary outcome measures extracted were early morbidity and mortality, pulmonary hemodynamic and functional outcome indices prior to and after the operation, and survival data.
Of the 654 publications retrieved, 19 relevant papers (total number of 2729 patients) representing the most recent and complete data set from each institute, were included for appraisal and data extraction. No randomized controlled trials or matched comparative studies were identified. Thirty-day mortality ranged from 1.3% to 24% (median 8%). Residual pulmonary hypertension was reported in 11%-35% of patients after PTE. Pulmonary artery pressure and pulmonary vascular resistance significantly decreased after PTE in all studies. Before PTE, 60%-100% of patients were in NYHA functional class III or IV. This percentage decreased to 0%-21% after PTE. Five-year survival ranged from 74% to 89%.
The current literature suggests that PTE for patients with CTEPH is associated with acceptable perioperative morbidity and mortality rates and improved hemodynamic indices and survival when viewed against the prognosis associated with historical controls using medical therapy.
肺动脉血栓内膜剥脱术(PTE)是慢性血栓栓塞性肺动脉高压(CTEPH)患者的一种治疗选择。本系统评价旨在评估PTE治疗CTEPH的安全性和有效性。
进行系统评价,检索了六个电子数据库中1999年1月至2010年2月发表的研究。纳入所有呈现发病率和死亡率数据、生存数据或术前和术后肺血流动力学指标的文章。提取的主要结局指标为早期发病率和死亡率、手术前后的肺血流动力学和功能结局指标以及生存数据。
在检索到的654篇出版物中,纳入了19篇相关论文(共2729例患者),这些论文代表了每个机构最新且完整的数据集,用于评估和数据提取。未找到随机对照试验或匹配的对照研究。30天死亡率在1.3%至24%之间(中位数为8%)。PTE后11% - 35%的患者报告有残余肺动脉高压。在所有研究中,PTE后肺动脉压力和肺血管阻力显著降低。PTE前,60% - 100%的患者处于纽约心脏协会(NYHA)功能分级III或IV级。PTE后这一比例降至0% - 21%。五年生存率在74%至89%之间。
当前文献表明,与采用药物治疗的历史对照的预后相比,CTEPH患者接受PTE治疗的围手术期发病率和死亡率可接受,血流动力学指标改善,生存率提高。